Medical Council Step exam for International Medical Graduates / ECFMG Certification USMLE Step 3: Advanced Clinical Management & Computer-Based Case Simulations Syllabus

USMLE Step 3: Advanced Clinical Management & Computer-Based Case Simulations syllabus — full chapter and topic list

Expand any chapter to see its topics and sub-topics. This is the whole examinable outline for USMLE Step 3: Advanced Clinical Management & Computer-Based Case Simulations in Medical Council Step exam for International Medical Graduates / ECFMG Certification, not a summary of it.

1. 1

   Foundations of Independent Practice (FIP)

   4 topics

   • Biostatistics and epidemiology applied to practice
   • Interpretation of medical literature and pharmacology
   • Patient safety and quality in the practice setting
   • Social and systems-based foundations of care
2. 2

   Advanced Clinical Medicine (ACM) Across Settings

   4 topics

   • Management in ambulatory/office settings
   • Management in emergency department settings
   • Management in inpatient and ICU settings
   • Initial vs continued care decision points
3. 3

   Computer-Based Case Simulations (CCS)

   4 topics

   • CCS Software & Workflow
     • Ordering tests, treatments, and monitoring
     • Advancing simulated clock and location changes
     • Re-evaluating and adjusting management
   • Acute and emergent case management strategies
   • Chronic disease longitudinal management
   • Avoiding harmful or unnecessary interventions
4. 4

   Health Maintenance & Population Health

   4 topics

   • Age-appropriate preventive care and screening
   • Immunization across the lifespan
   • Risk factor modification and counseling
   • Disease surveillance and public health reporting

USMLE Step 3: Advanced Clinical Management & Computer-Based Case Simulations flashcards for Medical Council Step exam for International Medical Graduates / ECFMG Certification

25 of 50 cards from the USMLE Step 3: Advanced Clinical Management & Computer-Based Case Simulations deck — real questions with worked answers.

1. How is the sensitivity of a diagnostic test calculated, and what is it best used for clinically?

   Sensitivity = TP / (TP + FN) — the proportion of truly diseased people who test positive. Highly sensitive tests are best for ruling OUT disease when negative (SnNout).

2. How is specificity calculated, and what is its clinical rule of thumb?

   Specificity = TN / (TN + FP) — the proportion of truly healthy people who test negative. Highly specific tests are best for ruling IN disease when positive (SpPin).

3. Define positive predictive value (PPV) and state how disease prevalence affects it.

   PPV = TP / (TP + FP) — probability that a person with a positive test truly has disease. PPV rises as prevalence increases and falls as prevalence decreases.

4. Define negative predictive value (NPV) and its relationship to prevalence.

   NPV = TN / (TN + FN) — probability that a person with a negative test is truly disease-free. NPV rises as prevalence falls (lower pretest probability).

5. What are the formulas for the positive and negative likelihood ratios?

   LR+ = sensitivity / (1 − specificity); LR− = (1 − sensitivity) / specificity. LR+ >10 and LR− <0.1 produce large, often conclusive changes in disease probability.

6. Distinguish relative risk (RR) from the odds ratio (OR), and state which study designs use each.

   RR = risk in exposed / risk in unexposed (used in cohort/RCT). OR = odds of exposure in cases / odds in controls (used in case-control). OR approximates RR when disease is rare.

7. How are absolute risk reduction (ARR) and number needed to treat (NNT) calculated?

   ARR = control event rate − treatment event rate. NNT = 1 / ARR. NNT is the number of patients treated to prevent one additional bad outcome.

8. What is the difference between incidence and prevalence?

   Incidence = NEW cases over a time period among those at risk (measures risk/rate). Prevalence = ALL existing cases at a point in time (incidence × average duration).

9. Define a Type I and a Type II error in hypothesis testing.

   Type I (alpha) error = rejecting a true null hypothesis (false positive). Type II (beta) error = failing to reject a false null hypothesis (false negative).

10. What is statistical power, how is it calculated, and what increases it?

    Power = 1 − beta = probability of detecting a true effect. It increases with larger sample size, larger effect size, lower variability, and a higher alpha.

11. How is a 95% confidence interval interpreted for an odds ratio or relative risk?

    If the 95% CI for an OR/RR crosses 1.0, the result is not statistically significant. For a difference in means, crossing 0 indicates non-significance.

12. What is lead-time bias versus length-time bias in screening studies?

    Lead-time bias = apparent survival gain only because disease is detected earlier, not because death is delayed. Length-time bias = screening preferentially detects slow, indolent disease with better prognosis.

13. What is confounding, and name three ways to control for it.

    A confounder is independently associated with both exposure and outcome and is not on the causal pathway. Control via randomization, restriction, matching, stratification, or multivariable regression.

14. Which statistical test compares means between two independent groups versus three or more groups?

    Two groups: Student's t-test. Three or more groups: ANOVA. Categorical/proportional data: chi-square test.

15. What does intention-to-treat (ITT) analysis preserve in a randomized trial?

    ITT analyzes participants in their originally assigned groups regardless of adherence or dropout, preserving randomization and giving a real-world (more conservative) estimate of effect.

16. Rank the strength of evidence among RCT, cohort, case-control, and case series.

    From strongest to weakest: systematic review/meta-analysis of RCTs > single RCT > cohort study > case-control study > case series/case report (expert opinion is lowest).

17. What is a hazard ratio, and which analysis produces it?

    A hazard ratio compares the instantaneous event rate between two groups over time; it is derived from time-to-event (survival) analysis, typically Cox proportional hazards regression / Kaplan-Meier data.

18. In pharmacology, define volume of distribution (Vd) and its formula.

    Vd = amount of drug in body / plasma drug concentration. A large Vd indicates extensive tissue distribution (lipophilic/protein-bound peripherally); it determines the loading dose.

19. What is drug clearance and how does it relate to maintenance dosing?

    Clearance = rate of drug elimination / plasma concentration (volume cleared per unit time). Maintenance dose rate = clearance × target steady-state concentration.

20. How is a drug's half-life calculated, and how many half-lives reach steady state?

    t½ = (0.693 × Vd) / clearance. Steady state and ~94–97% elimination are reached in approximately 4–5 half-lives.

21. Differentiate zero-order from first-order elimination kinetics, giving a classic example of each.

    Zero-order: constant amount eliminated per time, independent of concentration (e.g., ethanol, phenytoin at high doses, aspirin overdose). First-order: constant FRACTION eliminated per time (most drugs).

22. Define therapeutic index and explain why a narrow one matters.

    Therapeutic index = TD50 / ED50 (or LD50/ED50). A narrow therapeutic index (e.g., warfarin, digoxin, lithium, phenytoin) means small dose changes risk toxicity, requiring monitoring.

23. Distinguish a competitive from a non-competitive antagonist on a dose-response curve.

    Competitive antagonist: shifts the agonist curve right, decreasing potency but Vmax/Emax is unchanged (surmountable). Non-competitive antagonist: lowers Emax/Vmax (insurmountable).

24. What is the difference between drug efficacy and potency?

    Efficacy = maximal effect a drug can produce (Emax). Potency = amount of drug needed to produce a given effect (EC50); a more potent drug works at a lower dose but may have equal efficacy.

25. Per the IOM/Reason 'Swiss cheese' model, what is the difference between an active error and a latent error?

    Active error: failure at the point of care (sharp end) with immediate effect (e.g., wrong dose given). Latent error: hidden system/design flaw (blunt end) that predisposes to failure (e.g., look-alike packaging).

See more USMLE Step 3: Advanced Clinical Management & Computer-Based Case Simulations flashcards →

Planning USMLE Step 3: Advanced Clinical Management & Computer-Based Case Simulations for Medical Council Step exam for International Medical Graduates / ECFMG Certification

USMLE Step 3: Advanced Clinical Management & Computer-Based Case Simulations (Medical Council Step exam for International Medical Graduates / ECFMG Certification) FAQ